Comparison of Nightstar Therapeutics plc (NITE) and TRACON Pharmaceuticals Inc. (NASDAQ:TCON)

Nightstar Therapeutics plc (NASDAQ:NITE) and TRACON Pharmaceuticals Inc. (NASDAQ:TCON) compete with each other in the Biotechnology sector. We will analyze and contrast their risk, institutional ownership, analyst recommendations, profitability, dividends, earnings and valuation.

Earnings and Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Nightstar Therapeutics plc N/A 0.00 36.86M -1.93 0.00
TRACON Pharmaceuticals Inc. 3.00M 6.68 34.96M -1.47 0.00

In table 1 we can see Nightstar Therapeutics plc and TRACON Pharmaceuticals Inc.’s gross revenue, earnings per share (EPS) and valuation.

Profitability

Table 2 demonstrates the return on assets, net margins and return on equity of Nightstar Therapeutics plc and TRACON Pharmaceuticals Inc.

Net Margins Return on Equity Return on Assets
Nightstar Therapeutics plc 0.00% -38.7% -35.1%
TRACON Pharmaceuticals Inc. -1,165.33% -75.2% -46.2%

Liquidity

Nightstar Therapeutics plc’s Current Ratio and Quick Ratio are 7.7 and 7.7 respectively. The Current Ratio and Quick Ratio of its competitor TRACON Pharmaceuticals Inc. are 3.6 and 3.6 respectively. Nightstar Therapeutics plc therefore has a better chance of paying off short and long-term obligations compared to TRACON Pharmaceuticals Inc.

Analyst Recommendations

The following table shown below contains the ratings and recommendations for Nightstar Therapeutics plc and TRACON Pharmaceuticals Inc.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Nightstar Therapeutics plc 0 6 0 2.00
TRACON Pharmaceuticals Inc. 0 0 0 0.00

Nightstar Therapeutics plc’s upside potential currently stands at 0.39% and an $25.58 consensus target price.

Insider & Institutional Ownership

Nightstar Therapeutics plc and TRACON Pharmaceuticals Inc. has shares held by institutional investors as follows: 52.2% and 65.7%. Insiders held 3.1% of Nightstar Therapeutics plc shares. On the other hand, insiders held about 0.4% of TRACON Pharmaceuticals Inc.’s shares.

Performance

In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Nightstar Therapeutics plc 58.46% 84.74% 75.59% 24.04% 100.32% 118.58%
TRACON Pharmaceuticals Inc. 20.56% 51.76% 16.22% -38.57% -47.35% 104.76%

For the past year Nightstar Therapeutics plc was more bullish than TRACON Pharmaceuticals Inc.

Summary

Nightstar Therapeutics plc beats TRACON Pharmaceuticals Inc. on 6 of the 10 factors.

Nightstar Therapeutics Limited, a clinical-stage gene therapy company, focuses on developing and commercializing novel one-time treatments for patients suffering from rare inherited retinal diseases. The companyÂ’s lead product candidate includes NSR-REP1 that has completed Phase 1/2 clinical trial for the treatment of patients with choroideremia. It is also developing NSR-RPGR that is in Phase 1/2 clinical trial for the treatment of patients with X-linked retinitis pigmentosa, an inherited X-linked recessive retinal disease; and NSR-BEST1, which is in preclinical development for the treatment of Best vitelliform macular dystrophy. The company has a collaboration agreement with University of Oxford for the assistance in conducting clinical trials with its retinal gene therapy candidates; and Preceyes B.V. for the development of a high-precision drug delivery technology in the eye. The company was founded in 2013 and is headquartered in London, the United Kingdom.

TRACON Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for cancer, wet age-related macular degeneration (AMD), and fibrotic diseases. Its lead product candidate is TRC105, an endoglin antibody, which is in Phase III clinical trials for angiosarcoma; randomized Phase II clinical trials for renal cell carcinoma; Phase II clinical trials for soft tissue sarcoma; Phase II clinical trials for gestational trophoblastic neoplasia; Phase I/II clinical trials for hepatocellular carcinoma; Phase I clinical trial for lung cancer; Phase I/II clinical trials for breast cancer; and Phase I/II clinical trials for wet AMD. The companyÂ’s other product candidates comprise TRC102, a small molecule that is in Phase II clinical trials for mesothelioma, Phase II clinical trials for glioblastoma, Phase I clinical trial for solid tumors and lymphomas, as well as Phase I clinical trial for lung cancer; and TRC253, a small molecule high affinity competitive inhibitor of wild type androgen receptor (AR) and multiple AR mutant receptors that is in Phase I/II clinical trials for the treatment prostate cancer. Its preclinical development products include TRC205, an endoglin antibody for the treatment of fibrotic diseases; and TRC694, an orally bioavailable inhibitor of NF-kB inducing kinase for the treatment of patients with hematologic malignancies, including myeloma. The company has a strategic licensing collaboration with Janssen Pharmaceutica N.V. to develop TRC253 and TRC694; and a license agreement with Santen Pharmaceutical Co., Ltd to develop, manufacture, and commercialize DE-122, the ophthalmic formulation of TRC105, for ophthalmology indications. The company was formerly known as Lexington Pharmaceuticals, Inc. and changed its name to TRACON Pharmaceuticals, Inc. in March 2005. TRACON Pharmaceuticals, Inc. was founded in 2004 and is headquartered in San Diego, California.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.